Scarica l'app Stockscreener
136.64
1.44%
-2.00
Dopo l'orario di chiusura:
136.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$138.64
Aprire:
$138.36
Volume 24 ore:
548.76K
Relative Volume:
0.80
Capitalizzazione di mercato:
$8.79B
Reddito:
$74.06M
Utile/perdita netta:
$-114.71M
Rapporto P/E:
-75.75
EPS:
-1.8039
Flusso di cassa netto:
$-117.90M
1 W Prestazione:
+0.39%
1M Prestazione:
+11.47%
6M Prestazione:
+67.04%
1 anno Prestazione:
+153.69%
Intervallo 1D:
$131.69
$138.37
Intervallo di 1 settimana:
$130.63
$139.92
Portata 52W:
$50.48
$143.29
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
136.64 | 8.72B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics Inc - TradingKey
Protagonist Therapeutics Market Sentiment - Benzinga España
Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PTGX|Protagonist Therapeutics Inc|Price:136.110|Chg%:+0.680 - TradingKey
Protagonist Therapeutics Inc (PTGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protagonist Therapeutics, Inc. Revenue Breakdown – NASDAQ:PTGX - TradingView
TradingKey - TradingKey
Protagonist Therapeutics Inc (PTGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
PTGX Pulls Back: Protagonist Therapeutics Holds Above Support After Modest DeclineDealer Gamma - dars.gov.et
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
PROTAGONIST THERAPEUTICS INC : JEFFERIES RAISES TARGET PRICE TO $172 FROM $121 - Bitget
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup - ChartMill
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com - Investing.com Australia
Liquidity Mapping Around (PTGX) Price Events - Stock Traders Daily
PROTAGONIST THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $155 FROM $100 - Bitget
Protagonist Therapeutics stock hits all-time high at 141.79 USD - Investing.com
Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Protagonist Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open - Sahm
Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com - Investing.com Canada
Citizens JMP Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan - Stock Titan
Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight - AlphaStreet
Protagonist Therapeutics Is Maintained at Overweight by Barclays - Moomoo
PTGX Maintained by Barclays -- Price Target Raised to $151 - GuruFocus
Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Best Momentum Stocks to Buy for July 13th - Yahoo Finance Singapore
Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Protagonist Therapeutics (PTGX) AGM 2026 Summary - Quartr
Protagonist Therapeutics (PTGX) Investor Update Summary - Quartr
Protagonist Therapeutics Inc. (PTGX) Q1 2026 Earnings: Surprise Profitability Defies Estimates, Yet Shares SlideEPS Consistency Score - dars.gov.et
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued - Yahoo Finance
New Strong Buy Stocks for July 9th - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest - simplywall.st
Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review FocusHas The Bull Case Changed? - Yahoo Finance
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains? - Yahoo Finance
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX) - The Globe and Mail
PTGX climbs as target hike adds to late-stage pipeline optimism - Quiver Quantitative
PTGX Stock Grinds Higher As Pipeline Catalysts Build - StocksToTrade
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com India
Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies - ad-hoc-news.de
Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally - AlphaStreet
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Protagonist Therapeutics Inc Azioni (PTGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Jun 23 '26 |
Sale |
117.94 |
9,000 |
1,061,460 |
7,825 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):